Why the study?
New biomarkers and therapeutic targets capable of identifying CKD early and delaying disease progression are urgently needed.
Periostin represents a potential novel biomarker for early renal tubular injury and a possible therapeutic target for delaying the progression of chronic kidney disease.
Hypothesis-generating for periostin in hypertensive nephropathy; requires prospective validation before any clinical use.
The continuous accumulation of extracellular matrix will eventually lead to glomerular sclerosis, interstitial fibrosis, tubular atrophy and vascular sclerosis, which are involved in the progression of chronic kidney disease (CKD). If these processes can be discovered early and effective interventions given in time, the progression of kidney disease may be delayed. Therefore, exploring new biomarkers and therapeutic targets that can identify CKD at an early stage is urgently needed. In recent years, studies have shown that urine periostin may be used as a marker of early renal tubular injury. And in an animal model experiment of hypertensive nephropathy, periostin is involved in the progression of kidney injury and reflects its progression. Here we review the current progress on the role of periostin in pathologic pathways of kidney system to explore whether periostin is a potential therapeutic target for the treatment of CKD.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: